Providing safe care to hereditary cancer patients and families
8 May 2019
Providing safe care to hereditary cancer patients and families
How genetic testing is guiding the use of PARP inhibitors
PET scanning: Advantages and challenges for brain tumours
Current treatment for brain tumours
How the WIN consortium achieves its goals
The translational element of the WIN consortium
Making oncology global with the WIN consortium
An overview of the WIN consortium
The WIN symposium 2019
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) with PD-L1 advanced NSCLC
Entrectinib in NTRK fusion-positive non-small cell lung cancer
Using CT imaging to find radiomic signatures in surgically resected NSCLC